菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

Single B Cell


Versatile Single B Cell Technology for Multi-Species Antibody Discovery

WuXi Biologics’ single B cell screening platform is powered by Bruker’s Beacon Optofluidic technology. This cutting-edge platform enables rapid antibody discovery from a wide range of host species with high versatility and flexibility, supporting a broad spectrum of therapeutic targets.

 

Key Features of Single B Cell Technology:

  • Multiplexed, function-first screening of antibodies from human, mouse, rat, rabbit, camelid, chicken, and more
  • Ultra-high-throughput screening of over 20,000 primary B cells per day
  • Accelerated discovery with antibody sequences obtained in two weeks
  • High sequence recovery rate, with over 90% of recombinant antibodies retaining original binding and functional profiles after initial screening

Single B Cell Service Details:

Service Item Turnaround Time Request A Quote 
Immunization 4-12 weeks Request A Quote
On-Chip Screening 1 day
Single B Cell Sequencing 1-2 weeks

Case Study #1: High-Affinity Antibody Discovery Using Rabbit Single B Cell Screening

We utilized rabbit single B cell screening to discover high-affinity monoclonal antibodies with superior binding kinetics and functional properties compared to benchmark antibodies. Through high-throughput SPR screening and functional assays, lead mAbs demonstrated exceptional binding characteristics and enhanced inhibitory activity.

 

Figure A: High-throughput (HTP) SPR screening for single B cell-derived monoclonal antibodies, illustrating a broad range of affinity distributions among screened antibodies.

Figure B: Functional assays of lead mAbs (Lead 1D3 and Lead 1C6) compared to benchmark antibodies (BMK1 and BMK2), demonstrating superior binding affinity. Lead 1D3 and Lead 1C6 also exhibited improved binding affinity and higher inhibition potency compared to benchmark antibodies.

Case Study #2: Ultra-High-Throughput Single B Cell Screening for Rapid Monoclonal Antibody Identification

We leveraged ultra-high-throughput single B cell screening to identify monoclonal antibodies targeting a tumor-associated antigen (TAA) for ADC development. By screening over 20,000 B cells in a single day, this platform enabled the rapid identification of high-affinity, functionally diverse lead mAbs with great therapeutic potential. The selected leads demonstrated strong tumor cell binding, diverse epitope binning, and promising cytotoxicity when conjugated to MMAE.

 

Figure A: uHTP single B cell screening workflow, including B cell loading, mouse IgG detection, cell-based binding assays, and BCR sequencing. Tumor cell binding analysis by FACS showed high-binding affinity of multiple lead antibodies compared to the benchmark (BMK1).

Figure B: Tumor cell cytotoxicity assay with Fab-MMAE conjugates. Lead mAbs exhibited strong dose-dependent cytotoxicity, demonstrating great potential for ADC therapeutics development.

Figure C: Epitope binning analysis of lead antibodies, demonstrating diverse binding epitopes are isolated from the screening campaign for various therapeutic applications.

Your Project. Our Expertise.